👪

Inheritance

1

X-linked susceptibility locus HP:0001417

MECP2 lies on Xq28, so individual alleles at this locus are transmitted on the X chromosome. AUTSX3 itself is a susceptibility label rather than a proven, fully penetrant Mendelian disorder: penetrance, recurrence risk, and sex-specific expressivity have not been established for the heterogeneous coding and regulatory variants grouped under this name. GeneReviews' X-linked inheritance statement applies to established pathogenic MECP2 disorders and is therefore only partial support for this broader historical label.

X-linked inheritance

Show evidence (1 reference)

PMID:20301670 SUPPORT Human Clinical

"MECP2 disorders are inherited in an X-linked manner."

Establishes the chromosomal inheritance of pathogenic MECP2 disorders but does not establish penetrance or recurrence risk for AUTSX3 susceptibility alleles.

◈

Mechanistic Hypotheses

1

Hypomorphic MECP2 coding or cis-regulatory variation as an autism susceptibility mechanism

hypomorphic_mecp2_autism_susceptibility EMERGING

Evidence balance 2 support 1 refute

Some coding or cis-regulatory MECP2 variants may produce a partial change in MeCP2 abundance or function that is milder than classic Rett-causing loss of function and contributes to autism. Historical support came from small candidate-gene cohorts and a family transmission study. A 2026 preprint provides direct human-neuron reporter-assay evidence for two noncoding variants, but a 2025 X-chromosome-wide common-variant study did not nominate MECP2 among its associated loci, and a 2026 analysis of more than 41,000 trios found MECP2 coding de novo burden to be female-specific. The model is therefore plausible and newly testable, but neither canonical nor a basis for assuming that all reported variants are causal.

Pathograph links

Function-Altering MECP2 Coding or Cis-Regulatory Variation -> Reduced or Altered MeCP2 Activity DIRECT A subset of coding or regulatory variants can reduce transcript abundance, protein stability, or another MeCP2 function; the direction cannot be assumed for an untested variant.

Reduced or Altered MeCP2 Activity -> Dysregulated Neuronal Gene Expression DIRECT Altered MeCP2 abundance or function can perturb its transcriptional-regulatory activity.

Dysregulated Neuronal Gene Expression -> Altered Synaptic and GABAergic Neuron Function INDIRECT UNKNOWN INTERMEDIATES Model systems suggest that transcriptional dysregulation perturbs synaptic maturation and inhibitory-neuron function.

Altered Synaptic and GABAergic Neuron Function -> Autistic Behavior INDIRECT UNKNOWN INTERMEDIATES The model-system circuit phenotype is hypothesized to contribute to autistic behavior in carriers of function-altering MECP2 alleles.

Show evidence (3 references)

PMID:19125863 SUPPORT Human Clinical

"has provided evidence for significant association (P = 0.009) for a three-marker SNP haplotype of MECP2 with autism/autism spectrum disorders"

Historical family-based association evidence for the susceptibility model.

PMID:42146591 SUPPORT In Vitro

"We identified two noncoding variants that change CRE activity, each with a male-biased phenotype."

Directly supports functional cis-regulatory candidates, but the source is a preprint and does not establish population penetrance or a discrete AUTSX3 syndrome.

PMID:39706197 REFUTE Human Clinical

"17 of which yielded association with ASD (GRPR, AP1S2, DDX53, HDAC8, PCDH19, PTCHD1, PCDH11X, PTCHD1-AS, DMD, SYAP1, CNKSR2, GLRA2, OFD1, CDKL5, GPRASP2, NXF5, and SH3KBP1)."

In a much larger common-variant X-chromosome study, MECP2 was not among the associated genes. This is indirect negative evidence against generalizing the earlier small haplotype result, not a direct refutation of rare or regulatory MECP2 effects.

?

Discussions and Knowledge Gaps

3

Does AUTSX3 delineate a reproducible clinical entity, or should it remain a legacy susceptibility label within the broader MECP2-related disorder spectrum?

KNOWLEDGE GAP OPEN gap_autsx3_nosologic_status

Attached to

pathophysiology#Function-Altering MECP2 Coding or Cis-Regulatory Variation

The direct literature does not define a consistent AUTSX3 phenotype beyond autism, and individual reports overlap Rett-spectrum or intellectual-disability presentations. No AUTSX3-specific frequency, natural-history, epidemiology, diagnostic, biomarker, management, trial, or prognosis data were identified through 2026-08-05. Rett and MECP2-duplication data are comparators, not substitutes.

Posed by codex Posed 2026-08-05T00:00:00Z

The falcon deep-research artifact was identity-consistent and reached the same scoping conclusion; its Rett-specific prevalence, survival, regression, and trofinetide material was deliberately not promoted into this entry.

Show evidence (2 references)

PMID:12770674 SUPPORT Human Clinical

"These data provide additional evidence of variable expression in the Rett disorder phenotype"

The authors interpreted their autistic female cases as variable Rett expression rather than a new discrete syndrome.

PMID:17427193 SUPPORT Human Clinical

"supporting the notion that MECP2 mutations underlie several neurodevelopmental disorders."

Supports a broad phenotypic spectrum rather than a sharply bounded AUTSX3 entity.

Which MECP2 coding or regulatory variants reproducibly increase autism risk, with what penetrance and sex-specific effect?

KNOWLEDGE GAP OPEN gap_autsx3_evidence_robustness

Attached to

pathophysiology#Function-Altering MECP2 Coding or Cis-Regulatory Variation pathophysiology#Reduced or Altered MeCP2 Activity

Historical association studies were small and pre-GWAS. Modern results are informative but do not collapse into one claim: the 2025 XWAS did not nominate MECP2 as a common-variant locus; the 2026 trio analysis supports a female-specific coding de novo burden; the 2025 functional screen shows that only some ASD-catalogued missense variants lose function; and the 2026 cis-regulatory study is a preprint with two functional candidates. Large independent cohorts with allele-level segregation, penetrance, and phenotype data remain necessary. Reduced MeCP2 expression in a small postmortem autism cohort is relevant context but is non-specific across several neurodevelopmental disorders and does not establish an AUTSX3 causal node. Intellectual disability and absent speech therefore remain deliberately disconnected from the pathograph: both derive from one p.Gly206Ala carrier whose variant causality was not established.

Posed by codex Posed 2026-08-05T00:00:00Z

Show evidence (5 references)

PMID:17427193 SUPPORT Human Clinical

"which cause Rett syndrome (RTT), have been found in male and female autistic subjects without, however, a causal relation having unequivocally been established."

The historical study explicitly acknowledges uncertain causality.

PMID:39706197 SUPPORT Human Clinical

"We analyzed 418,652 X chromosome variants, identifying 59 associated with ASD"

Large modern common-variant evidence whose nominated genes did not include MECP2.

PMID:42032772 SUPPORT Human Clinical

"I analyzed DNVs in > 41,000 parent–child sequenced trios from three ASD family-based cohorts"

Establishes the scale of the modern sex-aware coding de novo analysis.

+ 2 more references

Do conditional or null Mecp2 models of Rett-spectrum loss reproduce the molecular and circuit effects of subtle AUTSX3-associated human variants?

HUMAN MODEL MISMATCH OPEN mismatch_autsx3_mecp2_loss_models

Attached to

pathophysiology#Altered Synaptic and GABAergic Neuron Function

The GABAergic conditional knockout establishes consequences of substantial cell-type-specific MeCP2 loss, while AUTSX3 proposes heterogeneous, often hypomorphic coding or regulatory alleles. The model is biologically relevant but may exaggerate dose, use a different cell-type distribution, and model Rett-like rather than nonsyndromic autism phenotypes.

Proposed experiments

Isogenic human-neuron AUTSX3 variant series

exp_autsx3_isogenic_human_neuron_variant_series

Introduce the candidate coding and cis-regulatory variants individually into the same human induced-pluripotent-stem-cell background, quantify allele-specific MECP2 expression and protein function, and compare excitatory and inhibitory neuron maturation with corrected isogenic lines.

Readouts

Allele-specific MECP2 expression

pathophysiology#Reduced or Altered MeCP2 Activity

Inhibitory synaptic function

pathophysiology#Altered Synaptic and GABAergic Neuron Function

Posed by codex Posed 2026-08-05T00:00:00Z

Show evidence (1 reference)

PMID:21068835 SUPPORT Model Organism

"mice lacking Mecp2 from GABA (γ-aminobutyric acid)-releasing neurons recapitulate numerous Rett syndrome and autistic features"

The available circuit evidence comes from a conditional knockout with Rett-spectrum features.

⚙

Pathophysiology

4

Function-Altering MECP2 Coding or Cis-Regulatory Variation

The AUTSX3 literature reports heterogeneous candidate alleles: de novo coding variants in autistic females, a segregating p.Gly206Ala missense variant in an autistic male, conserved 3'-UTR variants, and newer noncoding cis-regulatory candidates. Observation in an autistic individual is not by itself proof of causality, and functional effects are variant-specific.

Hypomorphic MECP2 coding or cis-regulatory variation as an autism susceptibility mechanism

MECP2 hgnc:6990

Downstream

Reduced or Altered MeCP2 Activity A subset of coding or regulatory variants can reduce transcript abundance, protein stability, or another MeCP2 function; the direction cannot be assumed for an untested variant.

Show evidence (3 references)

PMID:12770674 SUPPORT Human Clinical

"Two autistic disorder females were found to have de novo mutations in the MeCP2 gene."

Supports the observation of de novo MECP2 variants in two autistic females, not a distinct syndrome or proven variant mechanism.

PMID:17427193 SUPPORT Human Clinical

"We report 15 novel variants, not found in controls: one missense, two intronic, and 12 in the 3'UTR (seven in conserved nucleotides)."

Defines the heterogeneous variant classes observed in the Portuguese autism cohort.

PMID:42032772 SUPPORT Human Clinical

"three genes that were specific to females, for significance, including TAOK1, MECP2, and DDX3X within a variant class."

Modern large-cohort evidence supports MECP2 coding de novo burden in autistic females; it does not support a simple male-specific AUTSX3 model.

Reduced or Altered MeCP2 Activity

Functional effects differ by allele. Conserved 3'-UTR changes in four patients were associated with low MECP2 mRNA; a 2026 human-neuron reporter assay found a promoter candidate that reduced expression; and a 2025 yeast/Drosophila screen classified four of nine ASD-catalogued missense variants as loss of function while five retained function.

Hypomorphic MECP2 coding or cis-regulatory variation as an autism susceptibility mechanism

MECP2 hgnc:6990

methyl-CpG binding GO:0008327 ↕ DYSREGULATED

Downstream

Dysregulated Neuronal Gene Expression Altered MeCP2 abundance or function can perturb its transcriptional-regulatory activity.

Show evidence (3 references)

PMID:17427193 SUPPORT Human Clinical

"MECP2 mRNA levels measured in four patients with 3'UTR conserved changes were below the control range, suggesting an alteration in the stability of the transcripts."

Variant-associated transcript evidence for a dosage-reducing mechanism in four patients.

PMID:42146591 SUPPORT In Vitro

"One of these, a promoter variant, disrupts NFY binding and reduces MECP2 expression by ~30%, a magnitude that produces autism-like phenotypes in mice."

Human-neuron reporter-assay evidence from a 2026 preprint; clinical causality remains provisional.

PMID:40546018 SUPPORT Model Organism

"Our data predict that four ASD variants are loss of function and five are functional."

Demonstrates variant-specific functional heterogeneity and prevents treating every ASD-catalogued MECP2 missense variant as loss of function.

Dysregulated Neuronal Gene Expression

MeCP2 binds methylated DNA and participates in both transcriptional repression and activation. Altering MeCP2 activity can therefore change broad neuronal expression programs, but the specific transcriptional program connecting AUTSX3 candidate variants to autism has not been defined in human brain.

Hypomorphic MECP2 coding or cis-regulatory variation as an autism susceptibility mechanism

neuron CL:0000540

MECP2 hgnc:6990

regulation of gene expression GO:0010468 ↕ DYSREGULATED

Downstream

Altered Synaptic and GABAergic Neuron Function Model systems suggest that transcriptional dysregulation perturbs synaptic maturation and inhibitory-neuron function.

Show evidence (2 references)

PMID:9620804 SUPPORT In Vitro

"We show that a region of MeCP2 that localizes with the TRD associates with a corepressor complex containing the transcriptional repressor mSin3A and histone deacetylases."

Establishes a core MeCP2 transcriptional-repression mechanism in vitro.

PMID:18511691 SUPPORT Model Organism

"These studies suggest that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and that it can function as both an activator and a repressor of transcription."

Mouse evidence that MeCP2 has broad bidirectional transcriptional effects.

Altered Synaptic and GABAergic Neuron Function

Conditional Mecp2 deletion in mouse GABA-releasing neurons reduces inhibitory signaling and produces repetitive and other Rett/autism-like behaviors. This establishes a plausible circuit route for major MeCP2 loss, not a demonstrated human AUTSX3 mechanism for hypomorphic alleles.

Hypomorphic MECP2 coding or cis-regulatory variation as an autism susceptibility mechanism

GABAergic neuron CL:0000617

synapse organization GO:0050808 ↕ DYSREGULATED

Downstream

Autistic Behavior The model-system circuit phenotype is hypothesized to contribute to autistic behavior in carriers of function-altering MECP2 alleles.

Show evidence (1 reference)

PMID:21068835 SUPPORT Model Organism

"These data demonstrate that MeCP2 is critical for normal function of GABA-releasing neurons and that subtle dysfunction of GABAergic neurons contributes to numerous neuropsychiatric phenotypes."

Model-organism evidence for the GABAergic branch; human AUTSX3 translation remains unproven.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

3

Autistic Behavior HP:0000717

Show evidence (2 references)

PMID:19125863 SUPPORT Human Clinical

"This suggests that one or more functional variants of MECP2 existing at significant frequencies in the population may confer increased risk of autism/autism spectrum disorders"

Historical susceptibility association, retained with the evidence-balance caveats in the mechanistic hypothesis.

PMID:15211631 SUPPORT Human Clinical

"These mutations suggest that a possible association between MECP2 mutations and autism may warrant further study."

The source itself frames the association as provisional.

Intellectual Disability HP:0001249

Show evidence (1 reference)

PMID:17427193 SUPPORT Human Clinical

"was present in one autistic male with severe mental retardation and absence of language"

Single-carrier, variant-specific phenotype evidence with uncertain causal attribution.

Absent Speech HP:0001344

Show evidence (1 reference)

PMID:17427193 SUPPORT Human Clinical

"was present in one autistic male with severe mental retardation and absence of language"

Single-carrier, variant-specific phenotype evidence with uncertain causal attribution.

🧬

Genetic Associations

1

MECP2

Gene: MECP2 hgnc:6990 relationship_type: SUSCEPTIBILITY

Show evidence (3 references)

PMID:17427193 SUPPORT Human Clinical

"Our results suggest that MECP2 can play a role in autism etiology, although very rarely, supporting the notion that MECP2 mutations underlie several neurodevelopmental disorders."

Supports a rare contribution while explicitly limiting its scope.

PMID:42032772 SUPPORT Human Clinical

"Direct comparisons of DNVs in males and females revealed MECP2 as the only exome-wide significant gene"

Large-cohort evidence for sex-dependent MECP2 coding de novo burden in autism cohorts.

PMID:39706197 SUPPORT Human Clinical

"Here, we conducted an X-chromosome-wide association study (XWAS) using whole-genome sequencing data from 6,873 individuals with ASD (82% males) across Autism Speaks MSSNG, Simons Simplex Collection (SSC), and Simons Powering Autism Research (SPARK), alongside 8,981 population controls (43% males)."

Provides the scale of the modern common-variant study that did not nominate MECP2 among its associated genes.

💊

Medical Actions

1

Phenotype-Directed Multidisciplinary Support

Action: supportive care Ontology label: Supportive Care NCIT:C15747

There is no AUTSX3-specific or genotype-corrective treatment. Support should be directed to the individual's diagnosed autism, communication, developmental, educational, behavioral, and other clinical needs. The cited GeneReviews recommendation is group-level MECP2 guidance and does not support importing Rett-specific drugs, surveillance schedules, or treatment effects into AUTSX3. GeneReviews' risperidone, melatonin, and QT-prolonging-drug guidance is not retained as an AUTSX3 recommendation because the direct literature does not establish agitation, sleep disturbance, prolonged QTc, or another AUTSX3-specific indication; those decisions belong to the individual's actual clinical diagnosis and findings.

Show evidence (1 reference)

PMID:20301670 SUPPORT Human Clinical

"Treatment is mainly symptomatic and focuses on optimizing the individual's abilities using a multidisciplinary approach that should also include psychosocial support for family members."

Group-level supportive-care guidance for MECP2 disorders; no AUTSX3-specific efficacy evidence exists.

🔬

Diagnosis

1

Phenotype-led genomic testing and MECP2 variant interpretation

AUTSX3 has no standalone clinical or molecular diagnostic criteria. In an autistic individual with developmental impairment, genomic testing may identify an MECP2 variant, but diagnosis requires variant-level interpretation and comparison with established MECP2 disorders. A catalogued or functionally altered variant does not automatically define AUTSX3 or prove that it caused autism.

genetic testing NCIT:C15709

Show evidence (1 reference)

PMID:20301670 SUPPORT Human Clinical

"The diagnosis of a MECP2 disorder is established by molecular genetic testing"

Supports testing for established MECP2 disorders, not a validated AUTSX3-specific test.

📊

Prevalence

1

Worldwide

Unknown Not yet documented

No AUTSX3-specific prevalence, incidence, penetrance, carrier frequency, sex ratio, ancestry distribution, or geographic distribution was identified in literature reviewed through 2026-08-05. Autism and Rett syndrome rates must not be substituted for this historical susceptibility label.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Autism, Susceptibility to, X-Linked 3:

Rett syndrome MONDO:0010726

Overlapping Features Rett syndrome is the definitive MECP2 loss-of-function relationship and has a characteristic regression phenotype, primarily in females. An autistic presentation with a pathogenic MECP2 variant may represent atypical Rett syndrome rather than AUTSX3; Rett natural history, prevalence, and treatment evidence must not be transferred without the Rett phenotype.

Show evidence (1 reference)

PMID:20301670 SUPPORT Human Clinical

"The spectrum of MECP2-related phenotypes in females ranges from classic Rett syndrome to variant Rett syndrome with a broader clinical phenotype (either milder or more severe than classic Rett syndrome) to mild learning disabilities"

Establishes the broad female MECP2 spectrum that can overlap an autism-predominant presentation.

PPM-X syndrome MONDO:0010235

Overlapping Features PPM-X is a distinct, variant-specific MECP2 disorder, classically associated with p.Ala140Val and intellectual disability, pyramidal/parkinsonian signs, psychosis, and macroorchidism. It should be used when that syndromic and allelic pattern is present rather than relabeling it AUTSX3.

Show evidence (1 reference)

PMID:20301670 SUPPORT Human Clinical

"the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability"

Distinguishes recognized male MECP2 phenotypes from the historical AUTSX3 label.

Severe neonatal-onset encephalopathy with microcephaly MONDO:0010397

Overlapping Features Hemizygous males with severe pathogenic MECP2 loss-of-function variants may have a relentless neonatal encephalopathy rather than isolated autism susceptibility. This is an established severe male MECP2 disorder and must not be interpreted as the expected course of AUTSX3.

Show evidence (1 reference)

PMID:20301670 SUPPORT Human Clinical

"Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course"

Defines the severe male MECP2 differential and its contrasting course.

MECP2 duplication syndrome MONDO:0010283

Overlapping Features MECP2 copy-number gain causes a distinct dosage-gain syndrome, predominantly in males, that can include autistic features. A duplication is not evidence for the proposed hypomorphic AUTSX3 mechanism.

Show evidence (1 reference)

PMID:20425814 SUPPORT Human Clinical

"MECP2 duplication syndrome is 100% penetrant in affected males and is associated with infantile hypotonia, severe to profound mental retardation, autism or autistic features, poor speech development, recurrent infections, epilepsy, progressive spasticity, and, in some cases, developmental regression."

Human clinical review establishing the distinct dosage-gain syndrome and its overlapping autistic features.

🐁

Animal Models

2

Conditional Mecp2 deletion in GABA-releasing neurons Mouse (Mus musculus) Conditional knockout

This conditional knockout supports a GABAergic contribution to phenotypes of major MeCP2 deficiency. It is a Rett-spectrum model, not an allele-matched AUTSX3 model, and therefore cannot establish that subtle human coding or regulatory variants use the same mechanism.

Species

Mouse (Mus musculus)

Genotype

Conditional Mecp2 deletion in GABA-releasing neurons

Genes

MECP2 hgnc:6990

Show evidence (1 reference)

PMID:21068835 SUPPORT Model Organism

"Here we show that mice lacking Mecp2 from GABA (γ-aminobutyric acid)-releasing neurons recapitulate numerous Rett syndrome and autistic features, including repetitive behaviours."

Defines the model and the phenotype it reproduces.

Transgenic functional assays of nine ASD-catalogued human MECP2 missense variants Fruit fly (Drosophila melanogaster) Transgenic variant screen

Drosophila and budding-yeast assays calibrated with pathogenic and benign controls separated four predicted loss-of-function variants from five functionally retained variants. The system is useful for variant triage but lacks mammalian DNA methylation and does not establish human penetrance or an AUTSX3 phenotype.

Species

Fruit fly (Drosophila melanogaster)

Genotype

Transgenic functional assays of nine ASD-catalogued human MECP2 missense variants

Genes

MECP2 hgnc:6990

Show evidence (1 reference)

PMID:40546018 SUPPORT Model Organism

"To assess these nine variants as risk alleles for ASD, we developed MECP2 variant functional assays using budding yeast and Drosophila."

Establishes the variant-screening model systems and their intended use.

{ }

Source YAML

click to show

name: Autism, Susceptibility to, X-Linked 3
creation_date: "2026-07-31T00:00:00Z"
description: >-
  Autism, susceptibility to, X-linked 3 (AUTSX3; OMIM 300496) is a historical
  susceptibility label linking autism to MECP2 at Xq28. It is not a
  well-delineated Mendelian syndrome and has no validated AUTSX3-specific
  diagnostic criteria, phenotype frequencies, natural history, prevalence,
  prognosis, biomarker, treatment, or clinical trial. The evidence comprises
  rare MECP2 variants observed in autistic individuals, small pre-GWAS
  candidate-gene studies, and newer variant-functional and large-cohort studies.
  These sources support an emerging model in which some hypomorphic coding or
  cis-regulatory variants alter MeCP2 dosage or function, but they do not justify
  treating every MECP2 variant, reduced MeCP2 expression in an autism cohort, or
  the clinical features of Rett syndrome as AUTSX3. Contemporary classification
  should instead use the individual's phenotype and variant mechanism to
  distinguish autism susceptibility from Rett syndrome, PPM-X syndrome, severe
  male MECP2 encephalopathy, and MECP2 duplication syndrome.
category: Complex
disease_term:
  preferred_term: autism, susceptibility to, X-linked 3
  term:
    id: MONDO:0010342
    label: autism, susceptibility to, X-linked 3
parents:
- Autism Spectrum Disorder
inheritance:
- name: X-linked susceptibility locus
  description: >-
    MECP2 lies on Xq28, so individual alleles at this locus are transmitted on
    the X chromosome. AUTSX3 itself is a susceptibility label rather than a
    proven, fully penetrant Mendelian disorder: penetrance, recurrence risk, and
    sex-specific expressivity have not been established for the heterogeneous
    coding and regulatory variants grouped under this name. GeneReviews'
    X-linked inheritance statement applies to established pathogenic MECP2
    disorders and is therefore only partial support for this broader historical
    label.
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 disorders are inherited in an X-linked manner."
    explanation: >-
      Establishes the chromosomal inheritance of pathogenic MECP2 disorders but
      does not establish penetrance or recurrence risk for AUTSX3 susceptibility
      alleles.
mechanistic_hypotheses:
- hypothesis_group_id: hypomorphic_mecp2_autism_susceptibility
  hypothesis_label: Hypomorphic MECP2 coding or cis-regulatory variation as an autism susceptibility mechanism
  status: EMERGING
  description: >-
    Some coding or cis-regulatory MECP2 variants may produce a partial change in
    MeCP2 abundance or function that is milder than classic Rett-causing loss of
    function and contributes to autism. Historical support came from small
    candidate-gene cohorts and a family transmission study. A 2026 preprint
    provides direct human-neuron reporter-assay evidence for two noncoding
    variants, but a 2025 X-chromosome-wide common-variant study did not nominate
    MECP2 among its associated loci, and a 2026 analysis of more than 41,000
    trios found MECP2 coding de novo burden to be female-specific. The model is
    therefore plausible and newly testable, but neither canonical nor a basis
    for assuming that all reported variants are causal.
  evidence:
  - reference: PMID:19125863
    reference_title: Methyl-CpG-binding protein 2 polymorphisms and vulnerability to autism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "has provided evidence for significant association (P = 0.009) for a three-marker SNP haplotype of MECP2 with autism/autism spectrum disorders"
    explanation: Historical family-based association evidence for the susceptibility model.
  - reference: PMID:42146591
    reference_title: A massively parallel reporter assay of MECP2 cis-regulatory elements reveals genetic candidates for male-biased autism.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We identified two noncoding variants that change CRE activity, each with a male-biased phenotype."
    explanation: >-
      Directly supports functional cis-regulatory candidates, but the source is a
      preprint and does not establish population penetrance or a discrete AUTSX3
      syndrome.
  - reference: PMID:39706197
    reference_title: Chromosome X-wide common variant association study in autism spectrum disorder.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "17 of which yielded association with ASD (GRPR, AP1S2, DDX53, HDAC8, PCDH19, PTCHD1, PCDH11X, PTCHD1-AS, DMD, SYAP1, CNKSR2, GLRA2, OFD1, CDKL5, GPRASP2, NXF5, and SH3KBP1)."
    explanation: >-
      In a much larger common-variant X-chromosome study, MECP2 was not among the
      associated genes. This is indirect negative evidence against generalizing
      the earlier small haplotype result, not a direct refutation of rare or
      regulatory MECP2 effects.
pathophysiology:
- name: Function-Altering MECP2 Coding or Cis-Regulatory Variation
  biological_scale: MOLECULAR
  mechanism_confidence: HYPOTHETICAL
  description: >-
    The AUTSX3 literature reports heterogeneous candidate alleles: de novo
    coding variants in autistic females, a segregating p.Gly206Ala missense
    variant in an autistic male, conserved 3'-UTR variants, and newer noncoding
    cis-regulatory candidates. Observation in an autistic individual is not by
    itself proof of causality, and functional effects are variant-specific.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  downstream:
  - target: Reduced or Altered MeCP2 Activity
    causal_link_type: DIRECT
    hypothesis_groups:
    - hypomorphic_mecp2_autism_susceptibility
    description: >-
      A subset of coding or regulatory variants can reduce transcript abundance,
      protein stability, or another MeCP2 function; the direction cannot be
      assumed for an untested variant.
  evidence:
  - reference: PMID:12770674
    reference_title: Identification of MeCP2 mutations in a series of females with autistic disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two autistic disorder females were found to have de novo mutations in the MeCP2 gene."
    explanation: Supports the observation of de novo MECP2 variants in two autistic females, not a distinct syndrome or proven variant mechanism.
  - reference: PMID:17427193
    reference_title: MECP2 coding sequence and 3'UTR variation in 172 unrelated autistic patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 15 novel variants, not found in controls: one missense, two intronic, and 12 in the 3'UTR (seven in conserved nucleotides)."
    explanation: Defines the heterogeneous variant classes observed in the Portuguese autism cohort.
  - reference: PMID:42032772
    reference_title: Sex-aware genome-wide assessment of de novo variants in autism across coding and noncoding regions.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "three genes that were specific to females, for significance, including TAOK1, MECP2, and DDX3X within a variant class."
    explanation: >-
      Modern large-cohort evidence supports MECP2 coding de novo burden in
      autistic females; it does not support a simple male-specific AUTSX3 model.
- name: Reduced or Altered MeCP2 Activity
  biological_scale: MOLECULAR
  mechanism_confidence: HYPOTHETICAL
  description: >-
    Functional effects differ by allele. Conserved 3'-UTR changes in four
    patients were associated with low MECP2 mRNA; a 2026 human-neuron reporter
    assay found a promoter candidate that reduced expression; and a 2025
    yeast/Drosophila screen classified four of nine ASD-catalogued missense
    variants as loss of function while five retained function.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  molecular_functions:
  - preferred_term: methyl-CpG binding
    term:
      id: GO:0008327
      label: methyl-CpG binding
    modifier: DYSREGULATED
  downstream:
  - target: Dysregulated Neuronal Gene Expression
    causal_link_type: DIRECT
    hypothesis_groups:
    - hypomorphic_mecp2_autism_susceptibility
    description: Altered MeCP2 abundance or function can perturb its transcriptional-regulatory activity.
  evidence:
  - reference: PMID:17427193
    reference_title: MECP2 coding sequence and 3'UTR variation in 172 unrelated autistic patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 mRNA levels measured in four patients with 3'UTR conserved changes were below the control range, suggesting an alteration in the stability of the transcripts."
    explanation: Variant-associated transcript evidence for a dosage-reducing mechanism in four patients.
  - reference: PMID:42146591
    reference_title: A massively parallel reporter assay of MECP2 cis-regulatory elements reveals genetic candidates for male-biased autism.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "One of these, a promoter variant, disrupts NFY binding and reduces MECP2 expression by ~30%, a magnitude that produces autism-like phenotypes in mice."
    explanation: Human-neuron reporter-assay evidence from a 2026 preprint; clinical causality remains provisional.
  - reference: PMID:40546018
    reference_title: Revealing function-altering MECP2 mutations in individuals with autism spectrum disorder using yeast and Drosophila.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our data predict that four ASD variants are loss of function and five are functional."
    explanation: Demonstrates variant-specific functional heterogeneity and prevents treating every ASD-catalogued MECP2 missense variant as loss of function.
- name: Dysregulated Neuronal Gene Expression
  biological_scale: CELLULAR
  mechanism_confidence: HYPOTHETICAL
  description: >-
    MeCP2 binds methylated DNA and participates in both transcriptional
    repression and activation. Altering MeCP2 activity can therefore change
    broad neuronal expression programs, but the specific transcriptional
    program connecting AUTSX3 candidate variants to autism has not been defined
    in human brain.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: regulation of gene expression
    term:
      id: GO:0010468
      label: regulation of gene expression
    modifier: DYSREGULATED
  downstream:
  - target: Altered Synaptic and GABAergic Neuron Function
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - hypomorphic_mecp2_autism_susceptibility
    description: Model systems suggest that transcriptional dysregulation perturbs synaptic maturation and inhibitory-neuron function.
  evidence:
  - reference: PMID:9620804
    reference_title: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We show that a region of MeCP2 that localizes with the TRD associates with a corepressor complex containing the transcriptional repressor mSin3A and histone deacetylases."
    explanation: Establishes a core MeCP2 transcriptional-repression mechanism in vitro.
  - reference: PMID:18511691
    reference_title: MeCP2, a key contributor to neurological disease, activates and represses transcription.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These studies suggest that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and that it can function as both an activator and a repressor of transcription."
    explanation: Mouse evidence that MeCP2 has broad bidirectional transcriptional effects.
- name: Altered Synaptic and GABAergic Neuron Function
  biological_scale: CELLULAR
  mechanism_confidence: HYPOTHETICAL
  description: >-
    Conditional Mecp2 deletion in mouse GABA-releasing neurons reduces
    inhibitory signaling and produces repetitive and other Rett/autism-like
    behaviors. This establishes a plausible circuit route for major MeCP2 loss,
    not a demonstrated human AUTSX3 mechanism for hypomorphic alleles.
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: synapse organization
    term:
      id: GO:0050808
      label: synapse organization
    modifier: DYSREGULATED
  downstream:
  - target: Autistic Behavior
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - hypomorphic_mecp2_autism_susceptibility
    description: The model-system circuit phenotype is hypothesized to contribute to autistic behavior in carriers of function-altering MECP2 alleles.
  evidence:
  - reference: PMID:21068835
    reference_title: Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These data demonstrate that MeCP2 is critical for normal function of GABA-releasing neurons and that subtle dysfunction of GABAergic neurons contributes to numerous neuropsychiatric phenotypes."
    explanation: Model-organism evidence for the GABAergic branch; human AUTSX3 translation remains unproven.
phenotypes:
- name: Autistic Behavior
  description: >-
    Autism is the defining phenotype of the susceptibility label. The evidence
    does not establish an AUTSX3-specific onset, severity distribution, or
    frequency, and individual MECP2-positive cases may meet criteria for a
    better-defined MECP2 disorder.
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:19125863
    reference_title: Methyl-CpG-binding protein 2 polymorphisms and vulnerability to autism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This suggests that one or more functional variants of MECP2 existing at significant frequencies in the population may confer increased risk of autism/autism spectrum disorders"
    explanation: Historical susceptibility association, retained with the evidence-balance caveats in the mechanistic hypothesis.
  - reference: PMID:15211631
    reference_title: "MECP2 structural and 3'-UTR variants in schizophrenia, autism and other psychiatric diseases: a possible association with autism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These mutations suggest that a possible association between MECP2 mutations and autism may warrant further study."
    explanation: The source itself frames the association as provisional.
- name: Intellectual Disability
  description: >-
    Severe intellectual disability was reported in the single autistic male
    carrying p.Gly206Ala. Because causal attribution of that segregating variant
    was not established, this is a variant-specific observation rather than an
    AUTSX3 frequency or severity claim.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:17427193
    reference_title: MECP2 coding sequence and 3'UTR variation in 172 unrelated autistic patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was present in one autistic male with severe mental retardation and absence of language"
    explanation: Single-carrier, variant-specific phenotype evidence with uncertain causal attribution.
- name: Absent Speech
  description: >-
    Absence of language was reported in the same p.Gly206Ala carrier. It is not
    established as a general AUTSX3 feature and no disease-level frequency is
    assigned.
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:17427193
    reference_title: MECP2 coding sequence and 3'UTR variation in 172 unrelated autistic patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was present in one autistic male with severe mental retardation and absence of language"
    explanation: Single-carrier, variant-specific phenotype evidence with uncertain causal attribution.
genetic:
- name: MECP2
  gene_term:
    preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  relationship_type: SUSCEPTIBILITY
  notes: >-
    MECP2 is the MONDO-linked susceptibility gene, but gene validity is
    phenotype-dependent. Its established role in MECP2 disorders does not by
    itself validate AUTSX3 as a separate disorder. Historical AUTSX3 evidence
    rests on small candidate-gene studies; modern evidence supports
    female-biased coding de novo burden and emerging, variant-specific
    cis-regulatory mechanisms.
    Variant classification must therefore be performed individually and should
    not use the AUTSX3 label to upgrade a variant of uncertain significance.
  evidence:
  - reference: PMID:17427193
    reference_title: MECP2 coding sequence and 3'UTR variation in 172 unrelated autistic patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results suggest that MECP2 can play a role in autism etiology, although very rarely, supporting the notion that MECP2 mutations underlie several neurodevelopmental disorders."
    explanation: Supports a rare contribution while explicitly limiting its scope.
  - reference: PMID:42032772
    reference_title: Sex-aware genome-wide assessment of de novo variants in autism across coding and noncoding regions.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Direct comparisons of DNVs in males and females revealed MECP2 as the only exome-wide significant gene"
    explanation: Large-cohort evidence for sex-dependent MECP2 coding de novo burden in autism cohorts.
  - reference: PMID:39706197
    reference_title: Chromosome X-wide common variant association study in autism spectrum disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we conducted an X-chromosome-wide association study (XWAS) using whole-genome sequencing data from 6,873 individuals with ASD (82% males) across Autism Speaks MSSNG, Simons Simplex Collection (SSC), and Simons Powering Autism Research (SPARK), alongside 8,981 population controls (43% males)."
    explanation: Provides the scale of the modern common-variant study that did not nominate MECP2 among its associated genes.
prevalence:
- population: Worldwide
  measure_type: UNKNOWN
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    No AUTSX3-specific prevalence, incidence, penetrance, carrier frequency, sex
    ratio, ancestry distribution, or geographic distribution was identified in
    literature reviewed through 2026-08-05. Autism and Rett syndrome rates must
    not be substituted for this historical susceptibility label.
diagnosis:
- name: Phenotype-led genomic testing and MECP2 variant interpretation
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: >-
    AUTSX3 has no standalone clinical or molecular diagnostic criteria. In an
    autistic individual with developmental impairment, genomic testing may
    identify an MECP2 variant, but diagnosis requires variant-level
    interpretation and comparison with established MECP2 disorders. A catalogued
    or functionally altered variant does not automatically define AUTSX3 or prove
    that it caused autism.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of a MECP2 disorder is established by molecular genetic testing"
    explanation: Supports testing for established MECP2 disorders, not a validated AUTSX3-specific test.
differential_diagnoses:
- name: Rett syndrome
  disease_term:
    preferred_term: Rett syndrome
    term:
      id: MONDO:0010726
      label: Rett syndrome
  description: >-
    Rett syndrome is the definitive MECP2 loss-of-function relationship and has
    a characteristic regression phenotype, primarily in females. An autistic
    presentation with a pathogenic MECP2 variant may represent atypical Rett
    syndrome rather than AUTSX3; Rett natural history, prevalence, and treatment
    evidence must not be transferred without the Rett phenotype.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The spectrum of MECP2-related phenotypes in females ranges from classic Rett syndrome to variant Rett syndrome with a broader clinical phenotype (either milder or more severe than classic Rett syndrome) to mild learning disabilities"
    explanation: Establishes the broad female MECP2 spectrum that can overlap an autism-predominant presentation.
- name: PPM-X syndrome
  disease_term:
    preferred_term: X-linked intellectual disability-psychosis-macroorchidism syndrome
    term:
      id: MONDO:0010235
      label: X-linked intellectual disability-psychosis-macroorchidism syndrome
  description: >-
    PPM-X is a distinct, variant-specific MECP2 disorder, classically associated
    with p.Ala140Val and intellectual disability, pyramidal/parkinsonian signs,
    psychosis, and macroorchidism. It should be used when that syndromic and
    allelic pattern is present rather than relabeling it AUTSX3.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability"
    explanation: Distinguishes recognized male MECP2 phenotypes from the historical AUTSX3 label.
- name: Severe neonatal-onset encephalopathy with microcephaly
  disease_term:
    preferred_term: severe neonatal-onset encephalopathy with microcephaly
    term:
      id: MONDO:0010397
      label: severe neonatal-onset encephalopathy with microcephaly
  description: >-
    Hemizygous males with severe pathogenic MECP2 loss-of-function variants may
    have a relentless neonatal encephalopathy rather than isolated autism
    susceptibility. This is an established severe male MECP2 disorder and must
    not be interpreted as the expected course of AUTSX3.
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course"
    explanation: Defines the severe male MECP2 differential and its contrasting course.
- name: MECP2 duplication syndrome
  disease_term:
    preferred_term: MECP2 duplication syndrome
    term:
      id: MONDO:0010283
      label: syndromic X-linked intellectual disability Lubs type
  description: >-
    MECP2 copy-number gain causes a distinct dosage-gain syndrome, predominantly
    in males, that can include autistic features. A duplication is not evidence
    for the proposed hypomorphic AUTSX3 mechanism.
  evidence:
  - reference: PMID:20425814
    reference_title: The MECP2 duplication syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MECP2 duplication syndrome is 100% penetrant in affected males and is associated with infantile hypotonia, severe to profound mental retardation, autism or autistic features, poor speech development, recurrent infections, epilepsy, progressive spasticity, and, in some cases, developmental regression."
    explanation: Human clinical review establishing the distinct dosage-gain syndrome and its overlapping autistic features.
treatments:
- name: Phenotype-Directed Multidisciplinary Support
  description: >-
    There is no AUTSX3-specific or genotype-corrective treatment. Support should
    be directed to the individual's diagnosed autism, communication,
    developmental, educational, behavioral, and other clinical needs. The cited
    GeneReviews recommendation is group-level MECP2 guidance and does not support
    importing Rett-specific drugs, surveillance schedules, or treatment effects
    into AUTSX3. GeneReviews' risperidone, melatonin, and QT-prolonging-drug
    guidance is not retained as an AUTSX3 recommendation because the direct
    literature does not establish agitation, sleep disturbance, prolonged QTc,
    or another AUTSX3-specific indication; those decisions belong to the
    individual's actual clinical diagnosis and findings.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:20301670
    reference_title: MECP2 Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment is mainly symptomatic and focuses on optimizing the individual's abilities using a multidisciplinary approach that should also include psychosocial support for family members."
    explanation: Group-level supportive-care guidance for MECP2 disorders; no AUTSX3-specific efficacy evidence exists.
animal_models:
- species: Mouse (Mus musculus)
  genotype: Conditional Mecp2 deletion in GABA-releasing neurons
  category: Conditional knockout
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  associated_phenotypes:
  - Repetitive behavior
  - Reduced inhibitory synaptic signaling
  - Rett-like neurologic features
  description: >-
    This conditional knockout supports a GABAergic contribution to phenotypes of
    major MeCP2 deficiency. It is a Rett-spectrum model, not an allele-matched
    AUTSX3 model, and therefore cannot establish that subtle human coding or
    regulatory variants use the same mechanism.
  evidence:
  - reference: PMID:21068835
    reference_title: Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here we show that mice lacking Mecp2 from GABA (γ-aminobutyric acid)-releasing neurons recapitulate numerous Rett syndrome and autistic features, including repetitive behaviours."
    explanation: Defines the model and the phenotype it reproduces.
- species: Fruit fly (Drosophila melanogaster)
  genotype: Transgenic functional assays of nine ASD-catalogued human MECP2 missense variants
  category: Transgenic variant screen
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  associated_phenotypes:
  - Variant-specific loss of function
  - Protein destabilization
  description: >-
    Drosophila and budding-yeast assays calibrated with pathogenic and benign
    controls separated four predicted loss-of-function variants from five
    functionally retained variants. The system is useful for variant triage but
    lacks mammalian DNA methylation and does not establish human penetrance or
    an AUTSX3 phenotype.
  evidence:
  - reference: PMID:40546018
    reference_title: Revealing function-altering MECP2 mutations in individuals with autism spectrum disorder using yeast and Drosophila.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "To assess these nine variants as risk alleles for ASD, we developed MECP2 variant functional assays using budding yeast and Drosophila."
    explanation: Establishes the variant-screening model systems and their intended use.
discussions:
- discussion_id: gap_autsx3_nosologic_status
  prompt: >-
    Does AUTSX3 delineate a reproducible clinical entity, or should it remain a
    legacy susceptibility label within the broader MECP2-related disorder
    spectrum?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Function-Altering MECP2 Coding or Cis-Regulatory Variation
  rationale: >-
    The direct literature does not define a consistent AUTSX3 phenotype beyond
    autism, and individual reports overlap Rett-spectrum or
    intellectual-disability presentations. No AUTSX3-specific frequency, natural-history,
    epidemiology, diagnostic, biomarker, management, trial, or prognosis data
    were identified through 2026-08-05. Rett and MECP2-duplication data are
    comparators, not substitutes.
  evidence:
  - reference: PMID:12770674
    reference_title: Identification of MeCP2 mutations in a series of females with autistic disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These data provide additional evidence of variable expression in the Rett disorder phenotype"
    explanation: The authors interpreted their autistic female cases as variable Rett expression rather than a new discrete syndrome.
  - reference: PMID:17427193
    reference_title: MECP2 coding sequence and 3'UTR variation in 172 unrelated autistic patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "supporting the notion that MECP2 mutations underlie several neurodevelopmental disorders."
    explanation: Supports a broad phenotypic spectrum rather than a sharply bounded AUTSX3 entity.
  posed_by: codex
  posed_date: "2026-08-05T00:00:00Z"
  notes: >-
    The falcon deep-research artifact was identity-consistent and reached the
    same scoping conclusion; its Rett-specific prevalence, survival, regression,
    and trofinetide material was deliberately not promoted into this entry.
- discussion_id: gap_autsx3_evidence_robustness
  prompt: >-
    Which MECP2 coding or regulatory variants reproducibly increase autism risk,
    with what penetrance and sex-specific effect?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Function-Altering MECP2 Coding or Cis-Regulatory Variation
  - pathophysiology#Reduced or Altered MeCP2 Activity
  rationale: >-
    Historical association studies were small and pre-GWAS. Modern results are
    informative but do not collapse into one claim: the 2025 XWAS did not
    nominate MECP2 as a common-variant locus; the 2026 trio analysis supports a
    female-specific coding de novo burden; the 2025 functional screen shows that
    only some ASD-catalogued missense variants lose function; and the 2026
    cis-regulatory study is a preprint with two functional candidates. Large
    independent cohorts with allele-level segregation, penetrance, and phenotype
    data remain necessary. Reduced MeCP2 expression in a small postmortem autism
    cohort is relevant context but is non-specific across several
    neurodevelopmental disorders and does not establish an AUTSX3 causal node.
    Intellectual disability and absent speech therefore remain deliberately
    disconnected from the pathograph: both derive from one p.Gly206Ala carrier
    whose variant causality was not established.
  evidence:
  - reference: PMID:17427193
    reference_title: MECP2 coding sequence and 3'UTR variation in 172 unrelated autistic patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "which cause Rett syndrome (RTT), have been found in male and female autistic subjects without, however, a causal relation having unequivocally been established."
    explanation: The historical study explicitly acknowledges uncertain causality.
  - reference: PMID:39706197
    reference_title: Chromosome X-wide common variant association study in autism spectrum disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We analyzed 418,652 X chromosome variants, identifying 59 associated with ASD"
    explanation: Large modern common-variant evidence whose nominated genes did not include MECP2.
  - reference: PMID:42032772
    reference_title: Sex-aware genome-wide assessment of de novo variants in autism across coding and noncoding regions.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "I analyzed DNVs in > 41,000 parent–child sequenced trios from three ASD family-based cohorts"
    explanation: Establishes the scale of the modern sex-aware coding de novo analysis.
  - reference: PMID:42146591
    reference_title: A massively parallel reporter assay of MECP2 cis-regulatory elements reveals genetic candidates for male-biased autism.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These findings suggest noncoding MECP2 variants can cause non-syndromic, male-biased autism"
    explanation: Emerging direct regulatory evidence, explicitly retained at preprint/partial strength.
  - reference: PMID:17486179
    reference_title: Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A significant reduction in MeCP2 expression compared to age-matched controls was found in 11/14 autism (79%), 9/9 RTT (100%), 4/4 Angelman syndrome (100%), 3/4 Prader-Willi syndrome (75%), 3/5 Down syndrome (60%), and 2/2 attention deficit hyperactivity disorder (100%) frontal cortex samples."
    explanation: The broad cross-disorder finding is relevant to dosage plausibility but is not specific evidence for AUTSX3 or for a variant-mediated causal path.
  posed_by: codex
  posed_date: "2026-08-05T00:00:00Z"
- discussion_id: mismatch_autsx3_mecp2_loss_models
  prompt: >-
    Do conditional or null Mecp2 models of Rett-spectrum loss reproduce the
    molecular and circuit effects of subtle AUTSX3-associated human variants?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Altered Synaptic and GABAergic Neuron Function
  rationale: >-
    The GABAergic conditional knockout establishes consequences of substantial
    cell-type-specific MeCP2 loss, while AUTSX3 proposes heterogeneous, often
    hypomorphic coding or regulatory alleles. The model is biologically relevant
    but may exaggerate dose, use a different cell-type distribution, and model
    Rett-like rather than nonsyndromic autism phenotypes.
  proposed_experiments:
  - experiment_id: exp_autsx3_isogenic_human_neuron_variant_series
    name: Isogenic human-neuron AUTSX3 variant series
    description: >-
      Introduce the candidate coding and cis-regulatory variants individually
      into the same human induced-pluripotent-stem-cell background, quantify
      allele-specific MECP2 expression and protein function, and compare
      excitatory and inhibitory neuron maturation with corrected isogenic lines.
    readouts:
    - name: Allele-specific MECP2 expression
      target: pathophysiology#Reduced or Altered MeCP2 Activity
    - name: Inhibitory synaptic function
      target: pathophysiology#Altered Synaptic and GABAergic Neuron Function
  evidence:
  - reference: PMID:21068835
    reference_title: Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "mice lacking Mecp2 from GABA (γ-aminobutyric acid)-releasing neurons recapitulate numerous Rett syndrome and autistic features"
    explanation: The available circuit evidence comes from a conditional knockout with Rett-spectrum features.
  posed_by: codex
  posed_date: "2026-08-05T00:00:00Z"
references:
- reference: PMID:20301670
  title: MECP2 Disorders.
  tags:
  - GeneReviews
- reference: PMID:39706197
  title: Chromosome X-wide common variant association study in autism spectrum disorder.
- reference: PMID:42032772
  title: Sex-aware genome-wide assessment of de novo variants in autism across coding and noncoding regions.
- reference: PMID:42146591
  title: A massively parallel reporter assay of MECP2 cis-regulatory elements reveals genetic candidates for male-biased autism.
- reference: PMID:40546018
  title: Revealing function-altering MECP2 mutations in individuals with autism spectrum disorder using yeast and Drosophila.
datasets: []

📚

References & Deep Research

References

5

PMID:20301670

MECP2 Disorders.

No top-level findings curated for this source.

PMID:39706197

Chromosome X-wide common variant association study in autism spectrum disorder.

No top-level findings curated for this source.

PMID:42032772

Sex-aware genome-wide assessment of de novo variants in autism across coding and noncoding regions.

No top-level findings curated for this source.

PMID:42146591

A massively parallel reporter assay of MECP2 cis-regulatory elements reveals genetic candidates for male-biased autism.

No top-level findings curated for this source.

PMID:40546018

Revealing function-altering MECP2 mutations in individuals with autism spectrum disorder using yeast and Drosophila.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 28 citations 2026-07-31T00:10:26.313200

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Autism, susceptibility to, X-linked 3 (AUTSX3; MECP2-related X-linked autism susceptibility)
MONDO ID: MONDO:0010342 (if available)
Category: Complex (X-linked genetic susceptibility; MECP2)

Research Objectives

Please provide a comprehensive research report on Autism, susceptibility to, X-linked 3 (AUTSX3; MECP2-related X-linked autism susceptibility) covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

AUTSX3 / MECP2-related X-linked autism susceptibility

Executive summary and curation warning

AUTSX3 (“autism susceptibility, X-linked 3”; OMIM 300496) is a historical phenotype label linking autism susceptibility to MECP2 at Xq28. Modern literature does not support it as a well-bounded disease with its own validated diagnostic criteria, phenotype frequencies, prevalence, natural history, or treatment evidence. It is better curated as a legacy MECP2-associated phenotype within the broader spectrum of male MECP2-related neurodevelopmental disorders, with explicit cross-references to Rett syndrome (RTT), severe neonatal encephalopathy, X-linked intellectual developmental disorder 13/PPM-X, and MECP2 duplication syndrome—but not treated as synonymous with any of them. Contemporary reviews explicitly list autism susceptibility (OMIM 300496) among male MECP2 phenotypes, while emphasizing a spectrum from mild intellectual impairment to neonatal encephalopathy and premature death. (pascualalonso2021mecp2relateddisordersin pages 2-4, pascualalonso2021mecp2relateddisordersin pages 1-2)

Accordingly, statistics and treatment results below are labeled either direct AUTSX3 evidence or MECP2-spectrum/RTT comparator evidence. RTT prevalence, survival, regression, and trofinetide data must not be entered as AUTSX3-specific facts.

Entity	Molecular lesion	Typical sex / inheritance	Defining phenotype / course	Evidence strength	Key caveat
AUTSX3 / autism susceptibility, X-linked 3 (OMIM 300496)	Historical MECP2-associated susceptibility label; not well delineated as a modern, discrete clinical entity in the gathered evidence	X-linked; historically associated with males carrying MECP2 variants, but current literature tends to subsume such cases under broader MECP2-related disorders (pascualalonso2021mecp2relateddisordersin pages 1-2, balicza2024multilevelevidenceof pages 1-2)	Autism/autistic features may occur with MECP2 variants, but the gathered evidence does not define a consistent standalone natural history, phenotype spectrum, prevalence, or diagnostic criteria for AUTSX3 specifically (pascualalonso2021mecp2relateddisordersin pages 1-2, pascualalonso2021mecp2relateddisordersin pages 11-12)	Sparse / historical	Do not transfer Rett syndrome prevalence, survival, or treatment data directly to AUTSX3; current evidence supports treating AUTSX3 as a legacy nosologic label within the wider MECP2-related disorder spectrum (pascualalonso2021mecp2relateddisordersin pages 1-2, pascualalonso2021mecp2relateddisordersin pages 11-12)
Rett syndrome due to MECP2 loss of function	MECP2 loss-of-function variants; >300 LOF variants documented, with 8 hotspot variants accounting for >60% of cases (gold2024rettsyndrome pages 3-4, gold2024rettsyndrome pages 1-2)	Predominantly females; X-linked dominant with major effect in heterozygous females; males usually require mosaicism or 47,XXY to present with classic RTT (coleman2022mosaicismofcommon pages 8-9, gold2024rettsyndrome pages 3-4, gold2024rettsyndrome pages 1-2)	Regression after early apparently typical development with loss of spoken language and purposeful hand use, hand stereotypies, gait impairment; chronic neurodevelopmental course with stabilization after regression and multisystem comorbidity burden (gold2024rettsyndrome pages 1-2, petriti2023globalprevalenceof pages 1-2, may2024characterizingthejourney pages 1-2)	Strong	RTT statistics apply to RTT, not to historical AUTSX3; X-inactivation modifies severity and blood XCI may not reflect brain disease (gold2024rettsyndrome pages 3-4, percy2024rettsyndromethe pages 2-3)
Severe neonatal encephalopathy in males (OMIM 300673)	Usually severe pathogenic MECP2 loss-of-function variants, often overlapping with classic female RTT-causing variants in hemizygous males (pascualalonso2021mecp2relateddisordersin pages 2-4, balicza2024multilevelevidenceof pages 1-2)	Typically 46,XY males; X-linked; often de novo	Severe early encephalopathy with neonatal/infantile onset, profound developmental impairment, ventilatory needs, and early death; considered among the most severe male MECP2 phenotypes (pascualalonso2021mecp2relateddisordersin pages 2-4, pascualalonso2021mecp2relateddisordersin pages 4-5, balicza2024multilevelevidenceof pages 1-2)	Moderate	Male MECP2 genotype-phenotype prediction remains limited; severity is broad and individual cases may not fit neatly into categories (coleman2022mosaicismofcommon pages 8-9, coleman2022mosaicismofcommon pages 8-8)
X-linked intellectual developmental disorder 13 / PPM-X (OMIM 300055)	Pathogenic MECP2 variants, including missense, truncating, and other alleles associated with non-classic male phenotypes (pascualalonso2021mecp2relateddisordersin pages 1-2, pascualalonso2021mecp2relateddisordersin pages 11-12, balicza2024multilevelevidenceof pages 1-2)	Usually males; X-linked	Cognitive impairment / intellectual disability with variable neurologic and behavioral involvement; may be static or less progressive than RTT/neonatal encephalopathy and may include autism-related features (pascualalonso2021mecp2relateddisordersin pages 2-4, pascualalonso2021mecp2relateddisordersin pages 11-12, balicza2024multilevelevidenceof pages 1-2)	Moderate	Boundaries with AUTSX3 and other historical MECP2 male diagnoses are blurred in modern literature; classification has shifted toward broader “MECP2-related disorders in males” (pascualalonso2021mecp2relateddisordersin pages 2-4, pascualalonso2021mecp2relateddisordersin pages 1-2)
MECP2 duplication syndrome (OMIM 300260)	Copy-number gain / duplication (or triplication) involving MECP2; dosage gain rather than loss of function (pascualalonso2021mecp2relateddisordersin pages 5-7)	Predominantly males; X-linked, often inherited from asymptomatic or mildly affected carrier mothers with skewed XCI (pascualalonso2021mecp2relateddisordersin pages 5-7, pascualalonso2021mecp2relateddisordersin pages 4-5)	Hypotonia, developmental delay, moderate-to-severe intellectual disability, poor/absent speech, autistic features, progressive spasticity, recurrent respiratory infections, GI problems, epilepsy in >50%, and possible motor regression/loss of ambulation over time (pascualalonso2021mecp2relateddisordersin pages 5-7)	Strong	Pathobiology is opposite in direction to RTT (gene dosage gain vs loss); should not be grouped with AUTSX3/RTT for prognosis or treatment assumptions (pascualalonso2021mecp2relateddisordersin pages 5-7, pascualalonso2021mecp2relateddisordersin pages 4-5)

Table: This table distinguishes the historical AUTSX3 label from better-supported MECP2-related entities. It is useful for preventing misclassification, especially the inappropriate reuse of Rett syndrome statistics for AUTSX3.

1. Disease information

Definition and identifiers

Preferred knowledge-base label: Autism susceptibility, X-linked 3 (AUTSX3), MECP2-associated.
OMIM: 300496.
Gene: MECP2, methyl-CpG binding protein 2; Xq28. Modern reviews identify MECP2 as dosage-sensitive: loss-of-function (LOF) produces RTT and related encephalopathies, whereas copy-number gain causes MECP2 duplication syndrome. (pascualalonso2021mecp2relateddisordersin pages 1-2, pascualalonso2021mecp2relateddisordersin pages 5-7)
MONDO: The user-supplied mapping is MONDO:0010342; it should be validated against the current MONDO release before production import because the literature retrieved here did not independently confirm that mapping.
Orphanet: No clearly supported AUTSX3-specific Orphanet entity was identified.
ICD-10/ICD-11, MeSH, SNOMED CT: No dedicated AUTSX3 code was identified. Coding should ordinarily reflect the observed clinical diagnosis—autism spectrum disorder, intellectual developmental disorder, Rett syndrome, or another defined MECP2-related disorder—rather than assuming these are equivalent.
Synonyms: AUTSX3; autism susceptibility, X-linked 3; MECP2-related X-linked autism susceptibility; MECP2-associated autism susceptibility.

Evidence provenance: AUTSX3 itself is represented mainly by aggregated disease-level resources and historical case literature. Current clinical and mechanistic understanding comes from aggregated MECP2/RTT literature, natural-history registries, individual male cases, cellular systems, and model organisms—not EHR-derived AUTSX3 cohorts.

2. Etiology, risk, protection, and environment

Causal and genetic factors

The strongest causal factor is a germline or post-zygotic MECP2 variant that alters MeCP2 abundance or function. For the historical AUTSX3 label, however, variant-specific causality and penetrance are insufficiently delineated. Male MECP2 disorders encompass missense, nonsense, frameshift, splice, deletion, mosaic, and dosage variants, and the same variant class can produce different clinical diagnoses. Pathogenic MECP2 variants have been estimated in approximately 2% of males with intellectual disability, but this is not an AUTSX3 prevalence or diagnostic yield. (pascualalonso2021mecp2relateddisordersin pages 11-12, balicza2024multilevelevidenceof pages 1-2)

Relevant genetic modifiers include:

Sex and hemizygosity: A 46,XY male has no second normal MECP2 allele.
Somatic mosaicism: It can attenuate an otherwise severe allele and permit survival. Two males with classic RTT were reported with mosaic c.730C>T (p.Gln244*) and c.397C>T (p.Arg133Cys) variants; male genotype–phenotype correlations remain too sparse for reliable prediction. (coleman2022mosaicismofcommon pages 8-9, coleman2022mosaicismofcommon pages 8-8)
47,XXY karyotype: A second X chromosome can permit a female-like RTT phenotype in males. (pascualalonso2021mecp2relateddisordersin pages 2-4)
X-chromosome inactivation (XCI): In heterozygous females, skewing modifies expressivity; blood XCI does not necessarily represent brain XCI. Up to 36% of one natural-history cohort showed significant skewing. (gold2024rettsyndrome pages 3-4, percy2024rettsyndromethe pages 2-3)
Allelic severity and protein domain: RTT comparator data associate R106W, R168, R255, and R270 with greater severity; R133C, R294, and R306C tend to be milder and T158M intermediate. These relationships cannot be transferred uncritically to males or AUTSX3. (gold2024rettsyndrome pages 3-4)

Non-genetic risk, protective factors, and gene–environment interaction

No reproducible environmental, occupational, dietary, lifestyle, infectious, vaccine-related, or toxin exposure has been established as a cause or specific modifier of AUTSX3. No validated protective MECP2 allele or environmental protective factor was identified. General developmental environment and access to early support may modify functional outcomes, but do not prevent the molecular disorder. The best-supported “gene–environment” effects are activity- and development-dependent neuronal consequences of altered epigenetic regulation, not a proven epidemiological exposure interaction.

3. Phenotypes

Directly defensible AUTSX3 phenotype

The narrowly defensible phenotype is early-onset neurodevelopmental impairment with autism/autistic features, variably accompanied by intellectual disability and speech or psychomotor delay. Modern male MECP2 literature stresses that manifestations range from mild cognitive impairment through progressive or neonatal encephalopathy; therefore, frequencies and a fixed progression pattern cannot be assigned to AUTSX3. (pascualalonso2021mecp2relateddisordersin pages 2-4, pascualalonso2021mecp2relateddisordersin pages 1-2)

Suggested ontology annotations:

Autism / autistic behavior — HP:0000717
Intellectual disability — HP:0001249
Global developmental delay — HP:0001263
Delayed speech and language development — HP:0000750
Abnormal social behavior — HP:0012433
Stereotypic behavior — HP:0000733
Hypotonia — HP:0001252
Seizure — HP:0001250, only where observed
Abnormality of gait — HP:0001288, only where observed

RTT/MECP2-spectrum comparator phenotype

Classic RTT requires regression followed by recovery or stabilization and four core features: loss of purposeful hand skills, loss of spoken language, gait abnormality, and stereotypic hand movements. Associated manifestations include seizures, breathing and autonomic abnormalities, cardiac abnormalities, sleep disturbance, growth deceleration, constipation, scoliosis, and autistic features. MECP2 variants are found in approximately 95–97% of typical RTT and about 85% of atypical RTT. These are comparator facts, not AUTSX3 criteria. (gold2024rettsyndrome pages 1-2, petriti2023globalprevalenceof pages 1-2)

Caregiver-priority data from 925 participants in the US natural-history study identified communication, seizures, walking/balance, hand use, and constipation as the major concerns, demonstrating substantial effects on independence and family quality of life. Concern rankings varied by age, severity, seizure activity, and MECP2 variant. This is RTT/related-disorder evidence.

Suggested additional HPO terms for an individual with RTT-like manifestations: loss of acquired skills (HP:0002376), hand stereotypies (HP:0000733), absent speech (HP:0001344), acquired microcephaly (HP:0005484), episodic hyperventilation (HP:0002883), bruxism (HP:0003763), constipation (HP:0002019), scoliosis (HP:0002650), and sleep disturbance (HP:0002360).

4. Genetic and molecular information

Gene and variants

MECP2 is the sole established gene attached to AUTSX3; suggested identifier HGNC:6990.
Pathogenicity must be assessed per ACMG/AMP criteria using phenotype, inheritance, population frequency, functional evidence, and ClinVar/ClinGen assertions. A MECP2 variant alone does not justify the AUTSX3 label.
Pathogenic MECP2 alleles are generally exceedingly rare or absent in population databases; exact gnomAD frequency must be reported variant-by-variant.
Most clinically causal variants are germline, commonly de novo in RTT. Post-zygotic somatic mosaicism is particularly important in surviving 46,XY males. (coleman2022mosaicismofcommon pages 8-9, coleman2022mosaicismofcommon pages 8-8)
More than 300 LOF variants are documented in RTT; eight recurrent variants account for over 60% of reported RTT cases. Variant classes include missense, nonsense, frameshift, splice, and large deletion. (gold2024rettsyndrome pages 3-4, gold2024rettsyndrome pages 1-2)
MECP2 duplications/triplications are a separate dosage-gain disorder. They should not be annotated as AUTSX3-causing variants. (pascualalonso2021mecp2relateddisordersin pages 5-7)

Functional consequences and epigenetics

MeCP2 binds methylated DNA, including neuronal non-CG methylation and 5-hydroxymethylcytosine contexts, organizes chromatin, recruits transcriptional coregulators, and modulates transcription rather than acting as a simple universal repressor. LOF perturbs long neuronal genes, synaptic programs, RNA processing, and cell homeostasis. The downstream phenotype is strongly influenced by XCI mosaicism in females and cell-type-specific MeCP2 requirements. (gold2024rettsyndrome pages 3-4, gold2024rettsyndrome pages 4-6, gold2024rettsyndrome pages 14-14)

No validated modifier gene is routinely used prognostically. TCF20-complex biology, BDNF/miR-132 feedback, and XCI regulators are plausible mechanistic modifiers, but not established clinical modifier tests.

5. Environmental, lifestyle, and infectious information

AUTSX3 is not an infectious, toxic, radiation-induced, or lifestyle disease. No pathogen, diet, smoking, alcohol, exercise pattern, or occupational exposure is established as causal. Environmental management—communication access, physical activity, nutrition, seizure safety, sleep support, and avoidance of medication-related respiratory or cardiac risk—can influence morbidity but not the underlying genotype. Vaccination is not implicated in causation.

6. Mechanism and pathophysiology

Causal chain

Upstream genetic event: pathogenic or function-altering MECP2 allele, mosaicism, or abnormal dosage.
Nuclear/epigenomic defect: abnormal methylated-DNA recognition, chromatin organization, transcriptional modulation, and interactions with coregulatory complexes.
Cellular dysregulation: altered BDNF/IGF1 signaling, mTOR–AKT activity, protein synthesis, synaptic maturation, neurotransmitter balance, mitochondrial respiration, lipid metabolism, calcium handling, and redox homeostasis. (gold2024rettsyndrome pages 4-6)
Circuit dysfunction: abnormal excitatory–inhibitory balance and impaired maturation/homeostasis across cortical and subcortical networks.
Clinical effects: impaired communication and cognition, stereotypies, motor dysfunction, seizures, autonomic and respiratory abnormalities, and—in severe RTT-like disease—regression.

Cell types and processes

Neurons: MeCP2 is abundant in mature neurons; deficient neurons are smaller, have shorter and less-branched dendrites and atypical spines. Suggested CL terms: neuron (CL:0000540), glutamatergic neuron (CL:0000679), GABAergic neuron (CL:0000617).
Astrocytes: Astrocyte-specific Mecp2 loss causes non-cell-autonomous neuronal injury, reversible after re-expression in mice. Human organoid/cell work shows mitochondrial abnormalities, impaired respiration, altered TCA/electron-transport proteins, amino-acid stress, and elevated ROS. Suggested term: astrocyte (CL:0000127). (gold2024rettsyndrome pages 3-4, gold2024rettsyndrome pages 4-6)
Microglia: MeCP2 deficiency can alter inflammatory signaling and glutamate release. Suggested term: microglial cell (CL:0000129). (gold2024rettsyndrome pages 4-6)
Oligodendroglial and other glial cells: likely contribute, but their AUTSX3-specific role is unquantified.

Suggested GO annotations include regulation of transcription by RNA polymerase II (GO:0006357), chromatin organization (GO:0006325), DNA methylation-dependent heterochromatin formation (GO:0006346), synapse organization (GO:0050808), regulation of synaptic plasticity (GO:0048167), mitochondrial electron transport (GO:0006120), cellular response to oxidative stress (GO:0034599), and nervous-system development (GO:0007399). Relevant cellular components include nucleus (GO:0005634), chromatin (GO:0000785), synapse (GO:0045202), postsynaptic density (GO:0014069), and mitochondrion (GO:0005739).

2023–2024 molecular profiling

A 2024 longitudinal single-nucleus RNA-seq study of Mecp2e1-mutant cortex found sixfold more differentially expressed genes in mutant females than males, female changes before overt symptoms, and dynamic non-cell-autonomous homeostatic effects. This is mouse-model evidence, not an AUTSX3 biomarker.
A 2024 human astrocyte/organoid multi-omics study found smaller mitochondria—especially in glia—reduced astrocytic respiration, altered TCA/electron-transport proteins, increased ROS, and effects of transferred mutant mitochondria on cortical-neuron activity.
A 2024 forebrain-organoid study using female MECP2 R255X hiPSCs and isogenic controls profiled days 0, 13, 40, and 75. RTT organoids showed late changes in EV hsa-miR-302/367 and strong C14MC upregulation, proposed as candidate progression biomarkers—not validated clinical tests. (sangani2024involvementofextracellular pages 1-3)
A 2024 PNAS meta-analysis of human-brain single-cell data found marked MECP2 expression variability across cell types, regions, developmental stages, and donors. This variability defines both a minimum restoration target and an upper toxicology margin for gene-restorative therapy. (zito2024variableexpressionof pages 1-2)
RettDb, released in 2024, integrates mouse Mecp2 genomic and transcriptomic datasets to support target discovery; it is a research resource rather than a diagnostic database.

Representative exact abstract wording includes: “Non-cell-autonomous effects were prominent and dynamic across disease progression” in the single-cell mouse study; and the organoid study reported that C14MC miRNAs showed “strong upregulation in RTT forebrain organoids.” (sangani2024involvementofextracellular pages 1-3)

7. Anatomical structures affected

The primary system is the central nervous system, particularly cerebral cortical networks. RTT comparator neuropathology shows globally reduced brain and neuronal size, higher neuronal packing density, reduced dendritic arborization, and atypical spines without a primary neurodegenerative pattern. MRI shows generalized volume reduction, selective dorsal parietal reduction, frontal volume–severity correlations, and white-matter tract abnormalities including the superior longitudinal fasciculus. (gold2024rettsyndrome pages 1-2, gold2024rettsyndrome pages 4-6)

Suggested anatomy terms:

Brain — UBERON:0000955
Cerebral cortex — UBERON:0000956
Frontal cortex — UBERON:0001870
Parietal cortex — UBERON:0001872
White matter — UBERON:0002316
Spinal cord — UBERON:0002240, where motor/autonomic involvement is documented
Skeletal muscle, gastrointestinal tract, heart, and respiratory system are secondary functional sites in severe MECP2 disorders.

There is no established lateralization pattern. Subcellular emphasis is nuclear chromatin, synaptic compartments, and mitochondria.

8. Temporal development

AUTSX3-specific course: not established. Autism and developmental delay ordinarily emerge in infancy or early childhood, but historical AUTSX3 does not have validated stages.

RTT comparator: development may appear relatively typical initially, followed by regression commonly beginning around 6–18 months, then partial recovery or stabilization and a chronic lifelong course. Head-growth deceleration can begin from the second month. Disease severity and motor dysfunction may continue to increase, especially during childhood and adolescence. (petriti2023globalprevalenceof pages 1-2, may2024characterizingthejourney pages 1-2, percy2024rettsyndromethe pages 2-3)

A 2024 real-world cohort of 455 females, followed for a median of four years, found an annual pediatric Clinical Severity Scale increase of 0.24 (95% CI 0.03–0.44), while Motor Behavioral Assessment scores increased 1.12/year (95% CI 0.63–1.60) in pediatric participants and 0.97/year (95% CI 0.53–1.41) in classic RTT. These values should not be assigned to AUTSX3. (may2024characterizingthejourney pages 1-2)

9. Inheritance and population

Inheritance

The locus is X-linked, but recurrence depends on the variant and parental status. Many severe LOF cases are de novo. Carrier females may be asymptomatic or variably affected because of XCI. A carrier mother can transmit the allele to 50% of pregnancies; sons receiving a pathogenic allele are hemizygous and may be more severely affected. Parental and low-level germline mosaicism make recurrence risk non-zero even when blood testing is negative.

Penetrance and expressivity for AUTSX3 are unknown. Male MECP2 expressivity is highly variable and cannot be reliably predicted from variant identity alone. Genetic anticipation and consanguinity are not established features. No AUTSX3 founder variant or carrier frequency is established. (coleman2022mosaicismofcommon pages 8-9, coleman2022mosaicismofcommon pages 8-8)

Epidemiology

No AUTSX3-specific prevalence, incidence, sex ratio, ethnic distribution, geographic clustering, or carrier frequency is available. This is likely partly due to obsolete/overlapping nosology.

For context only, a 2023 meta-analysis of ten RTT studies—9.57 million females and 673 cases—estimated RTT prevalence at 7.1 per 100,000 females (95% CI 4.8–10.5). RTT is almost exclusively diagnosed in females. This is not AUTSX3 epidemiology. (petriti2023globalprevalenceof pages 1-2)

10. Diagnostics

Clinical diagnosis

AUTSX3 has no standalone clinical criteria. Assess autism using standard DSM-5-TR/ICD-11 criteria and characterize development, cognition, language, movement, regression, hand stereotypies, breathing, sleep, seizures, feeding, growth, and autonomic function. A MECP2 finding should trigger phenotype-driven classification rather than automatic assignment of RTT or AUTSX3.

Recommended genetic approach

Trio exome or genome sequencing with copy-number and mosaic-variant calling is generally the most efficient approach for unexplained syndromic autism/developmental delay.
MECP2 sequencing with deletion/duplication analysis is appropriate where RTT, male MECP2 encephalopathy, or a familial MECP2 disorder is suspected.
Use high-depth NGS and consider digital PCR or an orthogonal deep assay when mosaicism is suspected; conventional Sanger sequencing may miss variants below approximately 15–20% allele fraction. (coleman2022mosaicismofcommon pages 8-9, pascualalonso2021mecp2relateddisordersin pages 4-5)
Chromosomal microarray detects MECP2-region deletions/duplications and other pathogenic CNVs. Whole-gene duplication suggests MDS, not AUTSX3.
Karyotype is useful in a male with a female-like RTT phenotype to detect 47,XXY.
RNA studies may resolve splice variants; methylation/XCI studies can be supportive in females but are not definitive because blood may not reflect brain.

FISH, mitochondrial DNA testing, repeat-expansion testing, biopsy, or metabolomics are not first-line AUTSX3 tests unless another differential diagnosis is suspected. Elevated lactate, muscle pathology, or respiratory-chain changes can occur in individual MECP2 cases but are neither sensitive nor specific. A 2024 male p.Arg179Trp case showed elevated exercise lactate, muscle histopathology, and transcriptomic oxidative-phosphorylation abnormalities. (balicza2024multilevelevidenceof pages 1-2)

Differential diagnosis

Important alternatives include classic/atypical RTT, MECP2 duplication syndrome, severe neonatal encephalopathy due to MECP2, CDKL5 deficiency disorder, FOXG1 syndrome, fragile X syndrome, Angelman syndrome, Phelan–McDermid syndrome, Pitt–Hopkins syndrome, other monogenic autism/ID syndromes, cerebral palsy, mitochondrial disease, and epileptic encephalopathy.

There is no validated newborn biochemical screen. Family-specific cascade, carrier, prenatal, and preimplantation testing are possible after a pathogenic variant is established.

11. Outcome and prognosis

No AUTSX3-specific survival, mortality, disability, recovery, or prognostic model exists. Prognosis should be individualized from sex, variant mechanism, mosaic fraction, neurological severity, seizures, feeding/respiratory status, mobility, and the best-fitting modern MECP2 diagnosis.

RTT comparator data indicate chronic disability rather than progressive neuronal death. Approximately 70% survive into their 50s, and survival exceeds 70% at age 45 in modern cohorts; cardiorespiratory disease is a major cause of death and sudden death accounts for an estimated 20–30% of deaths. These figures are not applicable to AUTSX3 without a Rett phenotype. (gold2024rettsyndrome pages 1-2, may2024characterizingthejourney pages 1-2)

In the 2024 US registry analysis, 44.6% had a hospital or emergency-room visit during follow-up. Pediatric participants used physical therapy more often than adults (87.3% versus 40.2%) and speech-language therapy (86.8% versus 23.9%), illustrating substantial lifelong functional burden and gaps in adult services. (may2024characterizingthejourney pages 1-2)

12. Treatment and applications

AUTSX3-specific treatment

There is no approved AUTSX3-specific or genotype-corrective therapy, no established pharmacogenomic algorithm, and no AUTSX3-specific randomized trial. Management is phenotype-directed:

autism-focused developmental and behavioral intervention;
augmentative and alternative communication;
speech-language, occupational, and physical therapy;
individualized education;
standard antiseizure treatment where required;
management of sleep, constipation, feeding, reflux, scoliosis, tone, mobility, anxiety, and respiratory/autonomic problems.

Suggested MAXO concepts include genetic counseling (MAXO:0001004), molecular genetic testing, developmental assessment, speech therapy, occupational therapy, physical therapy, augmentative communication, EEG, seizure management, nutritional management, and scoliosis surveillance; exact current MAXO identifiers should be verified before database import.

Rett comparator and recent developments

Trofinetide, a synthetic IGF1-derived tripeptide analogue, became the first FDA-approved RTT treatment on 10 March 2023. Phase III evidence showed statistically significant improvement in RTT Behaviour Questionnaire and clinician global-improvement outcomes, but it is symptomatic, not gene-corrective. Common clinically important adverse effects are diarrhea, vomiting, and weight loss, sometimes causing discontinuation. It is approved for RTT—not AUTSX3—and efficacy in an autistic male carrying a MECP2 variant cannot be assumed. (gold2024rettsyndrome pages 1-2, gold2024rettsyndrome pages 14-14)

Gene replacement, regulated AAV-MECP2 delivery, RNA editing, CRISPR-based editing, and selective reactivation of the normal inactive X are investigational. Because both deficiency and excess MECP2 are harmful, dose control and cell/region targeting are central safety constraints. Human-brain single-cell data reveal wide physiological MECP2 expression ranges that may help define therapeutic windows. (gold2024rettsyndrome pages 14-14, zito2024variableexpressionof pages 1-2)

A 2024 individual male p.Arg179Trp report described improvement of prominent negative psychiatric symptoms with cariprazine, but this is hypothesis-generating single-patient evidence, not a disease treatment recommendation. (balicza2024multilevelevidenceof pages 1-2)

13. Prevention

Primary prevention through lifestyle modification, vaccination, infection control, or medication is not available. Relevant measures are reproductive and secondary/tertiary prevention:

pre-test and post-test genetic counseling;
parental testing, including consideration of low-level mosaicism;
cascade testing in relatives;
prenatal diagnosis or preimplantation genetic testing for a known familial pathogenic variant;
early developmental surveillance and intervention;
prevention of complications through seizure safety, nutrition and aspiration assessment, mobility and bone-health support, scoliosis surveillance, sleep and respiratory assessment, and ECG/QTc review where clinically indicated.

No population newborn or universal carrier-screening program is established for AUTSX3. Risk-stratified family testing is more appropriate.

14. Other species and natural disease

No well-established naturally occurring AUTSX3-equivalent veterinary disease or breed predisposition was identified. MECP2 is evolutionarily conserved in vertebrates, but animal work largely uses engineered models. There is no infectious transmission, zoonotic potential, or cross-species contagion.

Useful taxa include human (NCBI Taxonomy 9606), house mouse (10090), rat (10116), zebrafish (7955), fruit fly (7227), and Caenorhabditis elegans (6239). Orthologue identifiers should be retrieved from the current NCBI Gene/Alliance release at ingestion time.

15. Model organisms and experimental systems

Models

Mouse: hemizygous null males, heterozygous females, conditional cell-type deletions, recurrent human-variant knock-ins, duplication models, and Mecp2e1 isoform models. They reproduce motor dysfunction, stereotypies, breathing abnormalities, seizures, altered social behavior, reduced growth, and shortened lifespan. Conditional restoration demonstrates substantial reversibility, supporting a disorder of neuronal maintenance/homeostasis rather than irreversible degeneration.
Rat and zebrafish: useful for behavior, respiration, development, pharmacology, and circuit analysis.
Drosophila/C. elegans: useful for conserved pathways and modifier screens, but they incompletely reproduce mammalian MeCP2/XCI biology.
Patient-derived iPSC neurons and astrocytes: preserve patient genotype and, in female clones, XCI state; useful for synaptic, mitochondrial, and drug studies.
Isogenic CRISPR-corrected lines: reduce background-genome confounding.
Cerebral/forebrain organoids: model human developmental timing, cell interactions, and extracellular-vesicle biomarkers. The 2024 R255X organoid study identified RTT-specific EV miRNA trajectories. (sangani2024involvementofextracellular pages 1-3)
Single-cell and spatial transcriptomics: resolve vulnerable neuronal and glial populations and non-cell-autonomous effects. (zito2024variableexpressionof pages 1-2)

Limitations

Male null mice progress rapidly and do not model female XCI mosaicism; heterozygous females are more clinically relevant but variable and slower. Rodent social behavior is not equivalent to human autism, and organoids lack mature vasculature, full immune representation, long-range circuitry, and lifelong maturation. Most models represent classic RTT-causing LOF, not the poorly defined historical AUTSX3 phenotype.

Knowledge-base conclusions

Curate AUTSX3 as a historical, sparse MECP2-associated autism susceptibility phenotype, not as a synonym for Rett syndrome.
Record OMIM 300496 and MECP2/HGNC:6990, but validate the supplied MONDO mapping before release.
Do not assign RTT prevalence, survival, regression frequencies, or trofinetide indication to AUTSX3.
Prefer a patient-specific modern diagnosis based on variant mechanism and phenotype: RTT, male MECP2 encephalopathy, MECP2-related intellectual developmental disorder, or MECP2 duplication syndrome.
Mark AUTSX3-specific incidence, penetrance, protective factors, variant frequencies, natural history, biomarkers, and treatment response as not established.

Key source URLs and publication dates

Pascual-Alonso et al., September 2021, MECP2-Related Disorders in Males: https://doi.org/10.3390/ijms22179610. (pascualalonso2021mecp2relateddisordersin pages 2-4, pascualalonso2021mecp2relateddisordersin pages 1-2)
Petriti et al., January 2023, global RTT prevalence meta-analysis: https://doi.org/10.1186/s13643-023-02169-6. (petriti2023globalprevalenceof pages 1-2)
May et al., July 2024, US real-world natural-history study: https://doi.org/10.1186/s11689-024-09557-6. (may2024characterizingthejourney pages 1-2)
Zito and Lee, February 2024, human-brain single-cell expression: https://doi.org/10.1073/pnas.2312757121. (zito2024variableexpressionof pages 1-2)
Sangani et al., September 2024, RTT brain-organoid EV miRNAs: https://doi.org/10.1007/s00018-024-05409-7. (sangani2024involvementofextracellular pages 1-3)
Gold et al., November 2024, Nature Reviews Disease Primers: https://doi.org/10.1038/s41572-024-00568-0. (gold2024rettsyndrome pages 3-4, gold2024rettsyndrome pages 1-2)
Balicza et al., January 2024, male MECP2 mitochondrial case: https://doi.org/10.3389/fpsyt.2023.1301272. (balicza2024multilevelevidenceof pages 1-2)

PMID note: PMID values were not exposed reliably in the retrieved full-text metadata; DOIs and journal dates are therefore supplied rather than risking incorrect PMID assignment.

References

(pascualalonso2021mecp2relateddisordersin pages 2-4): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.
(pascualalonso2021mecp2relateddisordersin pages 1-2): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.
(balicza2024multilevelevidenceof pages 1-2): Peter Balicza, Andras Gezsi, Mariann Fedor, Judit C. Sagi, Aniko Gal, Noemi Agnes Varga, and Maria Judit Molnar. Multilevel evidence of mecp2-associated mitochondrial dysfunction and its therapeutic implications. Frontiers in Psychiatry, Jan 2024. URL: https://doi.org/10.3389/fpsyt.2023.1301272, doi:10.3389/fpsyt.2023.1301272. This article has 8 citations.
(pascualalonso2021mecp2relateddisordersin pages 11-12): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.
(gold2024rettsyndrome pages 3-4): Wendy A. Gold, Alan K. Percy, Jeffrey L. Neul, Stuart R. Cobb, Lucas Pozzo-Miller, Jasmeen K. Issar, Bruria Ben-Zeev, Aglaia Vignoli, and Walter E. Kaufmann. Rett syndrome. Nov 2024. URL: https://doi.org/10.1038/s41572-024-00568-0, doi:10.1038/s41572-024-00568-0. This article has 82 citations.
(gold2024rettsyndrome pages 1-2): Wendy A. Gold, Alan K. Percy, Jeffrey L. Neul, Stuart R. Cobb, Lucas Pozzo-Miller, Jasmeen K. Issar, Bruria Ben-Zeev, Aglaia Vignoli, and Walter E. Kaufmann. Rett syndrome. Nov 2024. URL: https://doi.org/10.1038/s41572-024-00568-0, doi:10.1038/s41572-024-00568-0. This article has 82 citations.
(coleman2022mosaicismofcommon pages 8-9): Jessica A. Cooley Coleman, Timothy Fee, Renee Bend, Raymond Louie, Fran Annese, Jennifer Stallworth, Jessica Worthington, Caroline Black Buchanan, David B. Everman, Steven Skinner, Michael J. Friez, Julie R. Jones, and Catherine J. Spellicy. Mosaicism of common pathogenic mecp2 variants identified in two males with a clinical diagnosis of rett syndrome. American Journal of Medical Genetics Part A, 188:2988-2998, Aug 2022. URL: https://doi.org/10.1002/ajmg.a.62913, doi:10.1002/ajmg.a.62913. This article has 10 citations.
(petriti2023globalprevalenceof pages 1-2): Uarda Petriti, Daniel C. Dudman, Emil Scosyrev, and Sandra Lopez-Leon. Global prevalence of rett syndrome: systematic review and meta-analysis. Systematic Reviews, Jan 2023. URL: https://doi.org/10.1186/s13643-023-02169-6, doi:10.1186/s13643-023-02169-6. This article has 136 citations and is from a peer-reviewed journal.
(may2024characterizingthejourney pages 1-2): Damian May, Kalé Kponee-Shovein, Jeffrey L. Neul, Alan K. Percy, Malena Mahendran, Nathaniel Downes, Grace Chen, Talissa Watson, Dominique C. Pichard, Melissa Kennedy, and Patrick Lefebvre. Characterizing the journey of rett syndrome among females in the united states: a real-world evidence study using the rett syndrome natural history study database. Journal of Neurodevelopmental Disorders, Jul 2024. URL: https://doi.org/10.1186/s11689-024-09557-6, doi:10.1186/s11689-024-09557-6. This article has 11 citations and is from a peer-reviewed journal.
(percy2024rettsyndromethe pages 2-3): Alan K. Percy, Amitha Ananth, and Jeffrey L. Neul. Rett syndrome: the emerging landscape of treatment strategies. CNS Drugs, 38:851-867, Sep 2024. URL: https://doi.org/10.1007/s40263-024-01106-y, doi:10.1007/s40263-024-01106-y. This article has 41 citations and is from a peer-reviewed journal.
(pascualalonso2021mecp2relateddisordersin pages 4-5): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.
(coleman2022mosaicismofcommon pages 8-8): Jessica A. Cooley Coleman, Timothy Fee, Renee Bend, Raymond Louie, Fran Annese, Jennifer Stallworth, Jessica Worthington, Caroline Black Buchanan, David B. Everman, Steven Skinner, Michael J. Friez, Julie R. Jones, and Catherine J. Spellicy. Mosaicism of common pathogenic mecp2 variants identified in two males with a clinical diagnosis of rett syndrome. American Journal of Medical Genetics Part A, 188:2988-2998, Aug 2022. URL: https://doi.org/10.1002/ajmg.a.62913, doi:10.1002/ajmg.a.62913. This article has 10 citations.
(pascualalonso2021mecp2relateddisordersin pages 5-7): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.
(gold2024rettsyndrome pages 4-6): Wendy A. Gold, Alan K. Percy, Jeffrey L. Neul, Stuart R. Cobb, Lucas Pozzo-Miller, Jasmeen K. Issar, Bruria Ben-Zeev, Aglaia Vignoli, and Walter E. Kaufmann. Rett syndrome. Nov 2024. URL: https://doi.org/10.1038/s41572-024-00568-0, doi:10.1038/s41572-024-00568-0. This article has 82 citations.
(gold2024rettsyndrome pages 14-14): Wendy A. Gold, Alan K. Percy, Jeffrey L. Neul, Stuart R. Cobb, Lucas Pozzo-Miller, Jasmeen K. Issar, Bruria Ben-Zeev, Aglaia Vignoli, and Walter E. Kaufmann. Rett syndrome. Nov 2024. URL: https://doi.org/10.1038/s41572-024-00568-0, doi:10.1038/s41572-024-00568-0. This article has 82 citations.
(sangani2024involvementofextracellular pages 1-3): Nasim Bahram Sangani, Jarno Koetsier, Ana Rita Gomes, Maria Margarida Diogo, Tiago G. Fernandes, Freek G. Bouwman, Edwin C. M. Mariman, Mehrnaz Ghazvini, Joost Gribnau, Leopold M. G. Curfs, Chris P. Reutelingsperger, and Lars M. T. Eijssen. Involvement of extracellular vesicle microrna clusters in developing healthy and rett syndrome brain organoids. Cellular and Molecular Life Sciences: CMLS, Sep 2024. URL: https://doi.org/10.1007/s00018-024-05409-7, doi:10.1007/s00018-024-05409-7. This article has 15 citations.
(zito2024variableexpressionof pages 1-2): Antonino Zito and Jeannie T. Lee. Variable expression of mecp2, cdkl5, and fmr1 in the human brain: implications for gene restorative therapies. Proceedings of the National Academy of Sciences of the United States of America, Feb 2024. URL: https://doi.org/10.1073/pnas.2312757121, doi:10.1073/pnas.2312757121. This article has 15 citations and is from a highest quality peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

AUTSX3 / MECP2-related X-linked autism susceptibility

Executive summary and curation warning

1. Disease information

Definition and identifiers

2. Etiology, risk, protection, and environment

Causal and genetic factors

Non-genetic risk, protective factors, and gene–environment interaction

3. Phenotypes

Directly defensible AUTSX3 phenotype

RTT/MECP2-spectrum comparator phenotype

4. Genetic and molecular information

Gene and variants

Functional consequences and epigenetics

5. Environmental, lifestyle, and infectious information

6. Mechanism and pathophysiology

Causal chain

Cell types and processes

2023–2024 molecular profiling

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

Inheritance

Epidemiology

10. Diagnostics

Clinical diagnosis

Recommended genetic approach

Differential diagnosis

11. Outcome and prognosis

12. Treatment and applications

AUTSX3-specific treatment

Rett comparator and recent developments

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Models

Limitations

Knowledge-base conclusions

Key source URLs and publication dates

Artifacts